Physician profile
Jane E Bare
NPI 1295789493
$2,722.48
in general payments reported to CMS, 2019-2025
29 companies · $872 in 2025
The $872 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.54 · 2020: $25.76 · 2021: $311 · 2022: $515 · 2023: $387 · 2024: $583 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,841.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $385.42 | 2021-2024 | Mitraclip |
| Boston Scientific Corporation | $279.96 | 2019-2025 | Watchman Flx, General - Therapies |
| Irhythm Technologies, INC. | $193.49 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| E.R. Squibb & Sons, L.L.C. | $176.75 | 2024-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $173.44 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $169.66 | 2022-2025 | |
| Amgen INC. | $165.95 | 2021-2025 | Repatha |
| Merck Sharp & Dohme LLC | $155.29 | 2022-2025 | Verquvo, Belsomra, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.37 | 2020-2025 | Lifevest |
| Pfizer INC. | $126.99 | 2022-2025 | |
| Abiomed | $118.23 | 2023 | Impella |
| Astrazeneca Pharmaceuticals Lp | $96.57 | 2023-2025 | Farxiga, Wainua |
| Alnylam Pharmaceuticals INC. | $89.31 | 2025 | Onpattro, Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $61.20 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $52.04 | 2023-2024 | Inpefa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $38.88 | 2025 | Alphavac |
| Janssen Pharmaceuticals, INC | $38.19 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.65 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $36.28 | 2022-2023 | |
| Medtronic, INC. | $32.11 | 2021 | |
| Amarin Pharma, INC. | $30.49 | 2020-2022 | |
| Cvrx, INC. | $23.00 | 2024 | Barostim Neo System |
| Baxter Healthcare | $20.06 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Kestra Medical Technology Services, INC. | $17.91 | 2024 | Assure Wcd |
| Scpharmaceuticals INC. | $17.45 | 2024 | |
| Philips North America LLC | $15.40 | 2025 | Mcot |
| Daiichi Sankyo INC. | $14.04 | 2025 | Injectafer |
| Astellas Pharma US INC | $13.88 | 2019 | |
| Altathera Pharmaceuticals LLC | $12.47 | 2023 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Bare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.